Karyopharm Q4/FY2024 rev $145M; guides FY2025 rev $140-155M; trial updates

Karyopharm Therapeutics Inc.

2024-FY EPS reported -$0.93 revenue$145,237,000

FY2024 total revenue $145.2M (flat YoY); net product revenue $112.8M (vs $112M). Q4 net product rev $29.3M (+17% YoY).
FY2024 net loss $76.4M ($0.63 basic EPS) vs $143.1M ($1.25) prior year; cash $109.1M (Dec 2024) vs $192.4M.
Phase 3 SENTRY myelofibrosis trial: endpoint updated to Abs-TSS; top-line data expected 2H 2025; enrollment complete 1H 2025.
Phase 3 XPORT-EC-042 endometrial cancer trial modified: focus on pMMR/dMMR ineligible for checkpoint inhibitors; sample size 276; data mid-2026.
FY2025 guidance: total revenue $140-155M; US XPOVIO net product rev $115-130M; R&D+SG&A $240-255M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.